Radiotherapy With Extreme Hypofractionation in Patients With Breast Cancer in Brazil: a Retrospective Cohort Study

Launched by LATIN AMERICAN COOPERATIVE ONCOLOGY GROUP · Mar 8, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new way of giving radiotherapy to women with breast cancer in Brazil. Specifically, it looks at a treatment called extreme hypofractionation, where patients receive higher doses of radiation in fewer sessions—just five treatments instead of many more. The researchers want to see how effective this method is and what side effects patients might experience after their treatment.

To be part of this study, women must be over 18 years old and have been diagnosed with breast cancer. They should also be receiving this extreme hypofractionated radiotherapy after surgery, and their treatment should have started from December 2019 onwards. Participants can expect to have their health monitored closely, helping doctors understand how well this new treatment works and how it affects patients. This trial is currently looking for participants, and your involvement can contribute to important research that may improve breast cancer treatment in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Women over 18 years old;
• • Diagnosis of breast cancer of any molecular subtype;
• • Undergoing extreme hypofractionated radiotherapy (5 x 5.2Gy) postoperatively;
• • Treated from December/2019 onward;
• • With clinical and treatment data available in medical records.
• Exclusion Criteria:
• • The protocol does not provide exclusion criteria.